$12.00 (-2.20%)

Volume: 237.563k

Closed: Jan 27, 2023

Hollow Logo Score: 2.707
Cara Therapeutics Stock
$12.00 (-2.20%)

Volume: 237.563k

Closed: Jan 27, 2023

Score Hollow Logo 2.707
NASDAQ:CARA

Cara Therapeutics Stock News

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

11:00am, Monday, 12'th Sep 2022 GlobeNewswire Inc.
STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pat Read more
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – Read more
Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients with NP Presentation will highlight opportunity for oral dif Read more
Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica Oral presentation will include Read more
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Read more

7 Steps to Investing in Marijuana Stocks

07:19pm, Wednesday, 10'th Aug 2022 The Motley Fool
Here are seven steps to investing in the high-flying cannabis industry. Read more

Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

09:15pm, Monday, 08'th Aug 2022 Zacks Investment Research
Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? Read more

Cara Therapeutics Reports Second Quarter 2022 Financial Results

08:01pm, Monday, 08'th Aug 2022 GlobeNewswire Inc.
– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia Read more

Should You Buy Cara Therapeutics (CARA) Ahead of Earnings?

12:48pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. Read more
As scientific research continues to produce studies on the health benefits of cannabis and CBD and legalization of the plant grows across the globe, not unsurprisingly traditional investment firms are Read more

Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates

09:25pm, Monday, 09'th May 2022 Zacks Investment Research
Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? Read more

Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

01:05pm, Wednesday, 04'th May 2022 Zacks Investment Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? Read more
STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives Read more
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6 Moderna Inc (NASDAQ: MRNA) submitt Read more
ST. GALLEN, Switzerland and STAMFORD, Conn., April 28, 2022 (GLOBE NEWSWIRE) --  Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that t Read more

Hot Stocks To Watch:

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE